Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.39 |
| ▸ | CTSA | P10619 | 2/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | IGFBP5 | P24593 | 1/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8072156 | 0.92 | GRM2 (0.42) | FFAR1CTSACD274GRM2KIT | |
| SCHEMBL8072151 | 0.91 | CD274 (0.37) | FFAR1CTSACD274GRM2KIT | |
| SCHEMBL3477920 | 0.89 | PDE4D (0.41) | FFAR1CTSACD274 | |
| SCHEMBL3467003 | 0.88 | CTSA (0.41) | FFAR1CTSAMRGPRX4 | |
| SCHEMBL3797530 | 0.86 | CTSA (0.42) | FFAR1CTSAMRGPRX4 | |
| SCHEMBL8066309 | 0.86 | MAP4K4 (0.42) | KIT | |
| SCHEMBL3791661 | 0.82 | PDE4D (0.44) | CTSACD274GRM2 | |
| SCHEMBL7913183 | 0.81 | MAPK1 (0.41) | — | |
| SCHEMBL3794094 | 0.81 | GRM2 (0.41) | CTSAMRGPRX4GRM2 | |
| SCHEMBL7917992 | 0.81 | ADORA2A (0.38) | FFAR1CTSAGRM2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120183522-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | DECODE GENETICS EHF (IS) | 2012-07-19 | — | — | US | disclosed |
| WO-2009067600-A2 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120183522-A1 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS | PDE4A, PDE4B, PDE3B | FFAR1 1170/4885CTSA 3286/4885CD274 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.